Glucotrack Prices $3 Million Public Offering to Fund Expansion
At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...
GlucoTrack prices offering of 2.6M shares of common stock at $1.15
Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...
Hosted on MSN2d
Glucotrack hits trial success for direct blood measuring CGM
The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...
Glucotrack sets terms for $3 million public stock offering
RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...
Taiwan News2d
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...
Yahoo Finance4d
GlucoTrack, Inc. (GCTK)
The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK ...
Nasdaq16d
Glucotrack, Inc. Achieves ISO 13485:2016 Certification, Enhancing Commitment to Quality in Diabetes Technology
Glucotrack, Inc., a medical technology company specializing in diabetes solutions, announced it has achieved ISO 13485:2016 certification from the British Standards Institute, marking a ...
Nasdaq8d
Glucotrack, Inc. Appoints Peter C. Wulff as Chief Financial Officer
Glucotrack, Inc., a medical technology company specializing in diabetes solutions, has appointed Peter C. Wulff as the new Chief Financial Officer, effective immediately. Wulff brings over 35 ...
ETF Daily News6d
Glucotrack, Inc. Announces 1-for-20 Reverse Stock Split
As a result of this reverse stock split, every 20 shares of Glucotrack’s common stock will be combined into one share. The number of outstanding shares will subsequently decrease proportionally ...
Morningstar8d
Glucotrack Announces Reverse Stock Split
RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...
Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor
Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...